Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency

Completed · Not applicable · Has a placebo group

Conditions studied: Convergence Insufficiency

In brief

Convergence insufficiency (CI) is a prevalent binocular vision disorder with symptoms that include double/blurred vision, eyestrain, and headaches when engaged in reading or other near work. CI is present in 4% of the population where approximately 27% of CI patients do not improve even with validated therapy. The project will quantitatively study changes in convergence eye movements and neural substrates before and after validated therapy in CI patients. This knowledge can lead to improvements in currently validated therapy, reduction in therapy sessions, and reduced healthcare costs.

Key facts

Study ID

NCT03593031

Run by

New Jersey Institute of Technology

People needed

100

Starts

2014-04-01

Expected to finish

2020-01-01

Last updated by the study team

2020-02-25

Who can join

Age: 18 and older, up to 35. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• diagnosis of symptomatic convergence insufficiency binocularly normal control

You may not qualify if…

• history of head trauma any systematic disease that can interfere with vergence or accommodation such as multiple sclerosis

Where it is running

• NJIT — Newark, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.